I sure hope they plan to give a "REAL" Q2 Corporate Update before the end of June. There was almost nothing new in this talk. Sure, DM mentioned that they have 6-7 promising follow on molecules with 2 prepared to go forward. But what does that mean? He still didn't check off his box in his milestone list for confirming a second follow on molecule or expand on the indications. DM mentioned that the first kidney clinical work will begin this month and that there will be a news release associated with this. But DM also said that the Renal Clinical Advisory board had just met for the first time and is still planning things. So I don't know what kidney clinical work can start this month if they are still in the early planning stage. Blah.

BearDownAZ